Executives from the 2015 and 2014 Manny Award winners and finalists share their views on a variety of industry-related topics.
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
Leadership representing the 2018 Manny Award agency and network winners and finalists share their views on various healthcare industry trends and developments.
The top pharmaceutical companies are trying to proactively tackle, through shifts in R&D strategy and other tactics, the healthcare demands of the future.
There were as many billion-dollar brands in 2017 as there have been in any other calendar year despite the cratering effects of massive patent cliffs in 2012 and 2015.
This yearly review analyzes recent developments, trends and outlooks in the areas of biotechnology, biosimilars, biopharmaceuticals, biologics, biomarkers and biobanks.
2017 was a very good year for many of the agencies profiled in this annual directory featuring the leading healthcare communications agencies. Some reported individual setbacks, but they were still able to overcome these. As a wave of new drugs and biologics hit the market, several of the top healthcare agencies supported their launches.
The top pharmaceutical companies are blurring the lines with biotech and have been engaging in many collaborations, acquisitions, and restructuring plans in the past year.
Humira during 2014 remained the world’s best-selling prescription medicine; Sovaldi vaulted into second place in its first full year on the market; Harvoni is challenging Humira for the 2015 sales crown.
The U.S. biotechnology arena is undergoing a record-breaking M&A cycle for the industry. After generating M&A activity valued at $235 billion during 2014, the U.S. biotech sector produced more than $100 billion in deals during first-quarter 2015.
As the pipelines of their pharmaceutical and biotech clients continue to yield new drugs for patients, agencies are also seeing their business grow.
Biologic medicines and immunotherapy are front and center amongst many of the R&D strategies and platforms for the industry’s leading developers.
The industry’s patent cliffs have become less steep, but the Affordable Care Act will give pharma new challenges.
Fluidity was the state of pharmaceutical advertising in 2013, as agencies shifted their operations, personnel, and tactics to meet the needs of their clients, driven by the pace of digital.
The worldwide drug-delivery arena is growing each year as the increasing aging population is in need of improved methods of administration for products and therapies.
From big pharma to smaller specialty entities, contract manufacturing serves as a strategy for various industry players.